NET vs. DOCS, WIX, YOU, CNIC, SLP, SRAD, GVP, ARBB, CYN, and INSE
Should you be buying Netcall stock or one of its competitors? The main competitors of Netcall include Dr. Martens (DOCS), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Sylvania Platinum (SLP), Stelrad Group (SRAD), Gabelli Value Plus+ Trust (GVP), Arbuthnot Banking Group (ARBB), CQS Natural Resources Growth and Income (CYN), and Inspired (INSE). These companies are all part of the "computer software" industry.
Netcall vs. Its Competitors
Dr. Martens (LON:DOCS) and Netcall (LON:NET) are both small-cap computer software companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Dr. Martens presently has a consensus price target of GBX 6,000, suggesting a potential upside of 7,626.98%. Netcall has a consensus price target of GBX 138.33, suggesting a potential upside of 20.24%. Given Dr. Martens' higher possible upside, research analysts clearly believe Dr. Martens is more favorable than Netcall.
Dr. Martens has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Netcall has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
69.5% of Dr. Martens shares are held by institutional investors. Comparatively, 69.3% of Netcall shares are held by institutional investors. 4.4% of Dr. Martens shares are held by company insiders. Comparatively, 11.5% of Netcall shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Dr. Martens and Dr. Martens both had 2 articles in the media. Dr. Martens' average media sentiment score of 0.62 beat Netcall's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the media.
Dr. Martens has higher revenue and earnings than Netcall. Dr. Martens is trading at a lower price-to-earnings ratio than Netcall, indicating that it is currently the more affordable of the two stocks.
Netcall has a net margin of 14.99% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Netcall's return on equity.
Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.9%. Netcall pays an annual dividend of GBX 1 per share and has a dividend yield of 0.9%. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Netcall pays out 28.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Summary
Dr. Martens beats Netcall on 9 of the 17 factors compared between the two stocks.
Get Netcall News Delivered to You Automatically
Sign up to receive the latest news and ratings for NET and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:NET) was last updated on 7/3/2025 by MarketBeat.com Staff
